Researchers from Stanford University and the Veterans Affairs Palo Alto Health Care System in Palo Alto, Calif., warn that HIV antiretroviral treatment can worsen long-term hepatitis C infection and lead to drug-resistant strains of HCV, Drug Week reports. The investigators followed three groups of HIV and HCV coinfected patients--treatment-naive patients who began anti-HIV drugs at the beginning of the study, patients not taking any anti-HIV medications, and those who had already been on antiretroviral regimens before the study. The researchers found that the group that had been on anti-HIV therapy before the start of the study had higher and significantly more diverse HCV viral loads. They also had higher T-cell counts, which, while helping to control HIV replication, also appeared to be linked with a worsening of HCV infection. "These results suggest that there is no immediate effect of [highly active antiretroviral therapy] on HCV, but that with prolonged HAART, immune restoration results in an increase in HCV load and quasi-species diversity," the researchers concluded. The full report, titled "Impact of Highly Active Antiretroviral Therapy and Immunologic Status on Hepatitis C Virus Quasi-Species Diversity in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients," can be seen in the Journal of Virology.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














